References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29
- Diep CH, Daniel AR, Mauro LJ, et al. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol 2015;54:31–53
- Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175–9
- Wong BR, Josien R, Lee SY, et al. TRANCE(tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075–80
- Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–76
- Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclasto-genesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci 1998;95:3597–602
- Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–319
- Fili S, Karalaki M, Schaller B. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer Lett 2009;283:10–19
- Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103:41–50
- González-Suárez E, Branstetter D, Armstrong A, et al. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelial and disrupts lumen formation in cultured epithelial acini. Mol Cel Biol 2007;27:1442–54
- Sigl V, Penninger JM. RANKL/RANK-from bone physiology to breast cancer. Cytokine Growth Factor Rev 2014;25:205–14
- Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 2011;22:188–94
- Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci 2003;100:9744–9
- Hu H, Wang J, Gupta A, et al. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase. Breast Cancer Res Treat 2014;146:515–23
- Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature 2010;465:803–7
- González-Suárez E. RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin Transl Oncol 2011;13:222–8
- Beleut M, Rajaram RD, Caikovski M, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci 2010;107:2989–94
- González-Suárez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103–107
- Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468:98–102
- Jones DH, Nakashima T, Sánchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692–6
- Omar HS, Shaker OG, Nassar YH, et al. The association between RANKL and osteoprotegerin gene polymorphisms with breast cancer. Mol Cell Biochem 2015;403:219–29
- Pfitzner BM, Branstetter D, Loibl S, et al. RANK expression as prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 2014;145:307–15
- Park HS, Lee A, Chae BJ, et al. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol 2014;110:807–12